First Light Asset Management Has Upped Oxford Immunotec Global Plc (OXFD) Holding By $447,213; Alexander & Baldwin (ALEX)’s Sentiment Is 0.93

April 18, 2018 - By Dolores Ford

Oxford Immunotec Global PLC (NASDAQ:OXFD) Logo

First Light Asset Management Llc increased Oxford Immunotec Global Plc (OXFD) stake by 6.12% reported in 2017Q4 SEC filing. First Light Asset Management Llc acquired 34,401 shares as Oxford Immunotec Global Plc (OXFD)’s stock declined 10.21%. The First Light Asset Management Llc holds 596,778 shares with $8.34M value, up from 562,377 last quarter. Oxford Immunotec Global Plc now has $342.29 million valuation. The stock increased 0.84% or $0.11 during the last trading session, reaching $13.23. About 42,083 shares traded. Oxford Immunotec Global PLC (NASDAQ:OXFD) has declined 19.42% since April 18, 2017 and is downtrending. It has underperformed by 30.97% the S&P500.

Alexander & Baldwin Inc (ALEX) investors sentiment decreased to 0.93 in 2017 Q4. It’s down -0.19, from 1.12 in 2017Q3. The ratio fall, as 75 investment professionals increased or started new equity positions, while 81 sold and decreased equity positions in Alexander & Baldwin Inc. The investment professionals in our database reported: 38.29 million shares, up from 37.86 million shares in 2017Q3. Also, the number of investment professionals holding Alexander & Baldwin Inc in top ten equity positions decreased from 3 to 0 for a decrease of 3. Sold All: 29 Reduced: 52 Increased: 50 New Position: 25.

Since February 15, 2018, it had 0 insider purchases, and 1 sale for $36,038 activity. $36,038 worth of stock was sold by SANDBERG RICHARD A on Thursday, February 15.

Among 4 analysts covering Oxford Immunotec (NASDAQ:OXFD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oxford Immunotec had 10 analyst reports since July 19, 2017 according to SRatingsIntel. Piper Jaffray maintained the stock with “Buy” rating in Monday, January 8 report. The firm has “Buy” rating given on Thursday, September 28 by BTIG Research. The stock of Oxford Immunotec Global PLC (NASDAQ:OXFD) has “Buy” rating given on Tuesday, October 31 by Robert W. Baird. Cowen & Co maintained it with “Buy” rating and $19.0 target in Wednesday, September 27 report. The rating was maintained by Cowen & Co on Tuesday, October 31 with “Buy”. The stock has “Buy” rating by Cowen & Co on Wednesday, August 16. As per Wednesday, July 19, the company rating was maintained by Cowen & Co. As per Thursday, October 19, the company rating was maintained by Robert W. Baird. The stock of Oxford Immunotec Global PLC (NASDAQ:OXFD) earned “Buy” rating by Cowen & Co on Monday, January 22.

Investors sentiment increased to 1.57 in 2017 Q4. Its up 0.44, from 1.13 in 2017Q3. It is positive, as 11 investors sold OXFD shares while 17 reduced holdings. 13 funds opened positions while 31 raised stakes. 23.93 million shares or 6.29% more from 22.51 million shares in 2017Q3 were reported. Wells Fargo & Mn holds 44,004 shares. Birchview Cap LP invested 1.04% in Oxford Immunotec Global PLC (NASDAQ:OXFD). 237,783 are held by Fosun. Kornitzer Cap Management Inc Ks reported 0.01% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). Wasatch Advsrs invested in 565,932 shares or 0.1% of the stock. Rhumbline Advisers reported 0% stake. Jpmorgan Chase reported 5,462 shares. Axa invested 0.05% in Oxford Immunotec Global PLC (NASDAQ:OXFD). 79,592 were accumulated by Vanguard Grp Inc Inc. Invesco Ltd accumulated 3.09 million shares. Perceptive Advsrs Limited Liability Corporation invested 0.23% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). Alliancebernstein Limited Partnership invested in 13,700 shares or 0% of the stock. Savings Bank Of America Corporation De holds 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 3,173 shares. 19,646 were reported by Manufacturers Life Ins The. Morgan Stanley, a New York-based fund reported 60,373 shares.

The stock decreased 0.21% or $0.05 during the last trading session, reaching $23.26. About 106,958 shares traded. Alexander & Baldwin, Inc. (ALEX) has declined 18.49% since April 18, 2017 and is downtrending. It has underperformed by 30.04% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 4 selling transactions for $756,716 activity.

Schneider Capital Management Corp holds 2.01% of its portfolio in Alexander & Baldwin, Inc. for 329,630 shares. Seabridge Investment Advisors Llc owns 202,594 shares or 1.22% of their US portfolio. Moreover, Stevens First Principles Investment Advisors has 0.85% invested in the company for 57,237 shares. The Delaware-based Reliance Trust Co Of Delaware has invested 0.68% in the stock. Fuller & Thaler Asset Management Inc., a California-based fund reported 1.76 million shares.

Oxford Immunotec Global PLC (NASDAQ:OXFD) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts